Clinical trial · Observational
Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening
NCT06971276CI-TRIAL-00109672SCAN-LITEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is to test a liquid biopsy assay for screening and classifying anal dysplasia from blood.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anal Dysplasia | Anal Intraepithelial Neoplasia | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (6)
- label
- Anal cancer
- description
- Screening patients diagnosed with anal squamous cell carcinoma (ASCC)
- label
- AIN3
- description
- Screening patients diagnosed with anal intraepithelial neoplasia 3 (AIN3)
- label
- AIN2
- description
- Screening patients diagnosed with anal intraepithelial neoplasia 2 (AIN2)
- label
- AIN1
- description
- Screening patients diagnosed with anal intraepithelial neoplasia 1 (AIN1)
- label
- HPV Infection
- description
- Screening patients diagnosed with HPV infection (no lesion)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Past or current anal HPV-positive population undergone anal dysplasia screening. * Control patients from the general population. Exclusion Criteria: * Not meeting inclusion criteria.
References
Publications (0)
Data not yet available
No reference posted for this study.